Clinical trials: Human Immunodeficiency Virus
Sarcoma, Kaposi, HIV Infections
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in…
- Trial name
- NCT00002319
- Testing
- Doxorubicin hydrochloride (liposomal)
- Where
- 33 sites in United States
- Sponsor
- Sequus Pharmaceuticals
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients
- Trial name
- NCT00642499
- Testing
- Dronabinol
- Where
- 36 sites in United States
- Volunteers
- 103 people
- Sponsor
- Solvay Pharmaceuticals
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00523211
- Testing
- Vicriviroc
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
HIV Infections, Chickenpox
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
- Trial name
- NCT00002315
- Testing
- Netivudine, Acyclovir
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Glaxo Wellcome
HIV Infection, Infection, Human Immunodeficiency Virus
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and…
- Trial name
- NCT00085943
- Testing
- LEXIVA (GW433908), Ritonavir, KALETRA
- Where
- 119 sites in United States, Austria and 12 more
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
- Trial name
- NCT00002097
- Testing
- Nystatin
- Where
- United States
- Sponsor
- Argus Pharmaceuticals
HIV Infections, Kidney Failure, Chronic
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure
To evaluate the safety, tolerance, and pharmacokinetics of Retrovir (AZT) administration in HIV-infected patients in renal failure receiving maintenance hemodialysis.
- Trial name
- NCT00002047
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy
The purpose of the study is to gain initial information on the tolerability and feasibility of high-concentration capsaicin patches for the treatment of painful HIV-associated neuropathy, whether resulting from HIV disease and/or…
- Trial name
- NCT00061152
- Testing
- Capsaicin Dermal Patch
- Where
- 3 sites in United States
- Sponsor
- NeurogesX
Candidiasis, Mycoses
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal…
- Conditions
- Candidiasis, Mycoses, HIV Infections
- Trial name
- NCT00002038
- Testing
- Fluconazole
- Where
- United States
- Sponsor
- Pfizer
Acquired Immunodeficiency Syndrome
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
The purpose of this study was to determine the effects of nevirapine treatment on the pharmacokinetics of methadone in HIV-1 infected, opioid-dependent adults who had been on a stable methadone maintenance therapy for at least…
- Trial name
- NCT00273988
- Testing
- nevirapine
- Where
- Ireland
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains
The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a current treatment regimen that…
- Trial name
- NCT00964327
- Testing
- TMC114
- Volunteers
- 42 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection.
- Trial name
- NCT00002046
- Testing
- Zidovudine
- Where
- 11 sites in United States
- Sponsor
- Glaxo Wellcome
Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
In Serono Study 24380, the antecedent protocol to Study 25373, patients were randomly assigned in a 3.0-to-1.0 ratio to Groups A and B.
- Trial name
- NCT01077960
- Testing
- Serostim
- Where
- 26 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- EMD Serono
HIV Infections
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.
- Trial name
- NCT00002119
- Testing
- WF10
- Where
- United States
- Sponsor
- Oxo Chemie GmbH
HIV Infections
Phase I/II Study of Curdlan Sulfate
To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses…
- Trial name
- NCT00002100
- Testing
- Curdlan sulfate
- Where
- United States
- Sponsor
- AJI Pharma USA
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00551330
- Testing
- Vicriviroc
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.